litlas
ログインアカウント作成

Michael Pfreundschuh

1978–2021 年に発表

127
論文数
36,608
被引用数
100
h 指数
127
i10 指数

被引用数

Michael Pfreundschuh の年別被引用数1979 年: 被引用 5 件1980 年: 被引用 1 件1981 年: 被引用 9 件1982 年: 被引用 8 件1983 年: 被引用 8 件1984 年: 被引用 5 件1985 年: 被引用 5 件1986 年: 被引用 1 件1987 年: 被引用 3 件1988 年: 被引用 2 件1989 年: 被引用 4 件1990 年: 被引用 3 件1991 年: 被引用 2 件1992 年: 被引用 5 件1993 年: 被引用 1 件1994 年: 被引用 7 件1995 年: 被引用 15 件1996 年: 被引用 11 件1997 年: 被引用 39 件1998 年: 被引用 76 件1999 年: 被引用 79 件2000 年: 被引用 133 件2001 年: 被引用 125 件2002 年: 被引用 172 件2003 年: 被引用 145 件2004 年: 被引用 86 件2005 年: 被引用 155 件2006 年: 被引用 108 件2007 年: 被引用 110 件2008 年: 被引用 171 件2009 年: 被引用 162 件2010 年: 被引用 205 件2011 年: 被引用 278 件2012 年: 被引用 270 件2013 年: 被引用 284 件2014 年: 被引用 339 件2015 年: 被引用 303 件2016 年: 被引用 303 件2017 年: 被引用 299 件2018 年: 被引用 255 件2019 年: 被引用 935 件2020 年: 被引用 980 件2021 年: 被引用 943 件2022 年: 被引用 680 件2023 年: 被引用 423 件2024 年: 被引用 663 件2025 年: 被引用 232 件2026 年: 被引用 6 件

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 2,744 件、この内訳の 22.7%ドイツ: 引用元論文 1,193 件、この内訳の 9.9%イタリア: 引用元論文 775 件、この内訳の 6.4%イギリス: 引用元論文 757 件、この内訳の 6.2%中国: 引用元論文 727 件、この内訳の 6%フランス: 引用元論文 668 件、この内訳の 5.5%カナダ: 引用元論文 456 件、この内訳の 3.8%スペイン: 引用元論文 438 件、この内訳の 3.6%スイス: 引用元論文 424 件、この内訳の 3.5%オランダ: 引用元論文 411 件、この内訳の 3.4%日本: 引用元論文 346 件、この内訳の 2.9%オーストラリア: 引用元論文 330 件、この内訳の 2.7%
0%22.7%その他 23.4%

機関

分野

  • Medicine74.4%
  • Biochemistry, Genetics and Molecular Biology13.7%
  • Immunology and Microbiology10.5%
  • Neuroscience0.2%
  • Computer Science0.2%
  • Chemistry0.2%
  • その他0.8%

トピック

  • Lymphoma Diagnosis and Treatment15.3%
  • CAR-T cell therapy research5.7%
  • Chronic Lymphocytic Leukemia Research5.1%
  • CNS Lymphoma Diagnosis and Treatment4.7%
  • Viral-associated cancers and disorders3.5%
  • Immunotherapy and Immune Responses3.2%
  • その他62.5%

共著者

全論文

検索で開く
  1. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    著者: Bjoern Chapuy, Chip Stewart, Andrew Dunford, Jaegil Kim, Atanas Kamburov, Robert Redd, Mike S. Lawrence, Margaretha G.M. Roemer, Amy J. Li, Marita Ziepert, Annette M. Staiger, Jeremiah A. Wala, Matthew D. Ducar, Ignaty Leshchiner, Ester Rheinbay, Amaro Taylor‐Weiner, Caroline A. Coughlin, Julian M. Hess, Chandra Sekhar Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam Tracy, Heike Horn, Paul Van Hummelen, Andrew L. Feldman, Brian K. Link, Anne J. Novak, James R. Cerhan, Thomas M. Habermann, Reiner Siebert, Andreas Rosenwald, Aaron R. Thorner, Matthew Meyerson, Todd R. Golub, Rameen Beroukhim, Gerald Wulf, German Ott, Scott J. Rodig, Stefano Monti, Donna Neuberg, Markus Loeffler, Michael Pfreundschuh, Lorenz Trümper, Gad Getz, Margaret A. Shipp - Nature Medicine 2018 被引用: 1,972

  2. Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    著者: Hervé Tilly, María Gomes da Silva, Umberto Vitolo, Andrew Jack, Michel Meignan, Armando López‐Guillermo, Jan Walewski, M. André, Peter Johnson, Michael Pfreundschuh, Marco Ladetto - Annals of Oncology 2015 被引用: 925

  3. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group

    著者: Michael Pfreundschuh, Lorenz Trümper, Anders Österborg, Ruth Pettengell, Marek Trněný, Kevin Imrie, Dávid Ma, Devinder Gill, Jan Walewski, Pier Luigi Zinzani, Rolf A. Stahel, Stein Kvaløy, Ofer Shpilberg, Ulrich Jaeger, Mads Hansen, Tuula Lehtinen, Armando López‐Guillermo, Claudia Corrado, Adriana Scheliga, Nöel Milpied, Myriam Mendila, Michelle Rashford, Evelyn Kuhnt, Markus Loeffler - The Lancet Oncology 2006 被引用: 2,085

  4. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group

    著者: Michael Pfreundschuh, Evelyn Kuhnt, Lorenz Trümper, Anders Österborg, Marek Trněný, Lois E. Shepherd, Devinder Gill, Jan Walewski, Ruth Pettengell, Ulrich Jaeger, Pier Luigi Zinzani, Ofer Shpilberg, Stein Kvaløy, Peter de Nully Brown, Rolf A. Stahel, Nöel Milpied, Armando López‐Guillermo, Viola Poeschel, Sandra Graß, Markus Loeffler, Niels Murawski - The Lancet Oncology 2011 被引用: 811

  5. Phase 2 study of the bispecific T-cell engager (BiTE) antibody blinatumomab in relapsed/refractory diffuse large B-cell lymphoma

    著者: Andreas Viardot, Marie-Elisabeth Goebeler, Georg Heß, Svenja Neumann, Michael Pfreundschuh, Nicole Adrian, Florian Zettl, M. Libicher, Cyrus Sayehli, Julia Stieglmaier, Alicia Zhang, Dirk Nagorsen, Ralf C. Bargou - Blood 2016 被引用: 366

  6. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60)

    著者: Michael Pfreundschuh, Jöerg Schubert, Marita Ziepert, Rudolf Schmits, Martin Mohren, Eva Lengfelder, Marcel Reiser, Christina Nickenig, Michael Clemens, Norma Peter, Carsten Bokemeyer, Hartmut Eimermacher, Anthony D. Ho, Martin Hoffmann, Roland Mertelsmann, Lorenz Trümper, Leopold Balleisen, Rüediger Liersch, Bernd Metzner, Frank Hartmann, Bertram Glaß, Viola Poeschel, Norbert Schmitz, Christian Ruebe, Alfred C. Feller, Markus Loeffler - The Lancet Oncology 2008 被引用: 1,135

  7. Whole-brain radiotherapy or autologous stem-cell transplantation as consolidation strategies after high-dose methotrexate-based chemoimmunotherapy in patients with primary CNS lymphoma: results of the second randomisation of the International Extranodal Lymphoma Study Group-32 phase 2 trial

    著者: Andrés J.M. Ferreri, Kate Cwynarski, Elisa Jacobsen Pulczynski, Christopher P. Fox, Elisabeth Schorb, Paul La Rosée, Mascha Binder, Alberto Fabbri, Valter Torri, Eleonora Minacapelli, Monica Falautano, Fiorella Ilariucci, Achille Ambrosetti, Alexander Röth, Claire Hemmaway, Peter Johnson, Kim Linton, Tobias Pukrop, Jette Sønderskov Gørløv, Monica Balzarotti, Georg Heß, Ulrich Keller, Stephan Stilgenbauer, Jens Panse, Alessandra Tucci, Lorella Orsucci, Francesco Pisani, Alessandro Levis, Stefan W. Krause, Hans‐Joachim Schmoll, Bernd Hertenstein, Mathias Rummel, Jeffery Smith, Michael Pfreundschuh, Giuseppina Cabras, F. Angrilli, Maurilio Ponzoni, Martina Deckert, Letterio S. Politi, Jürgen Finke, Michele Reni, Franco Cavalli, Emanuele Zucca, Gerald Illerhaus - The Lancet Haematology 2017 被引用: 381

  8. CNS International Prognostic Index: A Risk Model for CNS Relapse in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP

    著者: Norbert Schmitz, Samira Zeynalova, Maike Nickelsen, Roopesh Kansara, Diego Villa, Laurie H. Sehn, Bertram Glaß, David W. Scott, Randy D. Gascoyne, Joseph M. Connors, Marita Ziepert, Michael Pfreundschuh, Markus Loeffler, Kerry J. Savage - Journal of Clinical Oncology 2016 被引用: 445

  9. A testicular antigen aberrantly expressed in human cancers detected by autologous antibody screening

    著者: Yao‐Tseng Chen, Matthew J. Scanlan, Uğur Şahin, Özlem Türeci, Ali O. Güre, Solam Tsang, Barbara Williamson, Elisabeth Stockert, Michael Pfreundschuh, Lloyd J. Old - National Academy of Sciences, Proceedings of the National Academy of Sciences 1997 被引用: 1,245

  10. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    著者: Eva Hoster, Martin Dreyling, Wolfgang Hiddemann, Christian Gisselbrecht, Achiel Van Hoof, Hanneke C. Kluin‐Nelemans, Michael Pfreundschuh, Marcel Reiser, Bernd Metzner, Hermann Einsele, Norma Peter, Wolfram Jung, Bernhard Wörmann, Wolfgang Ludwig, Ulrich Dührsen, Hartmut Eimermacher, Hannes Wandt, Joerg Hasford, Wolfgang Hiddemann, Michael Unterhalt - Blood 2007 被引用: 971

  11. Treatment and prognosis of mature T-cell and NK-cell lymphoma: an analysis of patients with T-cell lymphoma treated in studies of the German High-Grade Non-Hodgkin Lymphoma Study Group

    著者: Norbert Schmitz, Lorenz Trümper, Marita Ziepert, Maike Nickelsen, Anthony D. Ho, Bernd Metzner, Norma Peter, Markus Loeffler, Andreas Rosenwald, Michael Pfreundschuh - Blood 2010 被引用: 592

  12. NAD(P)H Oxidase and Multidrug Resistance Protein Genetic Polymorphisms Are Associated With Doxorubicin-Induced Cardiotoxicity

    著者: Leszek Wojnowski, Bettina Kulle, Markus Schirmer, Gregor Schlüter, Albrecht Schmidt, Albert Rosenberger, Stefan Vonhof, Heike Bickeböller, Mohammad R. Toliat, Eun-Kyung Suk, Mladen V. Tzvetkov, Anke Krüger, S. Seifert, Marita Kloess, Heidi Hahn, Markus Loeffler, Peter Nürnberg, Michael Pfreundschuh, Lorenz Trümper, Jürgen Brockmöller, Gerd Hasenfuß - Circulation 2005 被引用: 488

  13. Four versus six cycles of CHOP chemotherapy in combination with six applications of rituximab in patients with aggressive B-cell lymphoma with favourable prognosis (FLYER): a randomised, phase 3, non-inferiority trial

    著者: Viola Poeschel, Gerhard Held, Marita Ziepert, Mathias Witzens‐Harig, Harald Holte, Lorenz Thurner, Peter Borchmann, Andreas Viardot, Martin Soekler, Ulrich Keller, Christian Schmidt, Lorenz Truemper, Rolf Mahlberg, Reinhard Marks, Heinz‐Gert Hoeffkes, Bernd Metzner, Judith Dierlamm, Norbert Frickhofen, Mathias Haenel, Andreas Neubauer, Michael Kneba, Francesco Merli, Alessandra Tucci, Peter de Nully Brown, Massimo Federico, Eva Lengfelder, Alice Di Rocco, Ralf Ulrich Trappe, Andreas Rosenwald, Christian Berdel, Martin Maisenhoelder, Ofer Shpilberg, Josif Amam, Konstantinos Christofyllakis, Frank Hartmann, Niels Murawski, Stephan Stilgenbauer, Maike Nickelsen, Gerald Wulf, Bertram Glaß, Norbert Schmitz, Bettina Altmann, Markus Loeffler, Michael Pfreundschuh - The Lancet 2019 被引用: 253

  14. High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology

    著者: David W. Scott, Rebecca L. King, Annette M. Staiger, Susana Ben‐Neriah, Aixiang Jiang, Heike Horn, Anja Mottok, Pedro Farinha, Graham W. Slack, Daisuke Ennishi, Norbert Schmitz, Michael Pfreundschuh, Grzegorz S. Nowakowski, Brad S. Kahl, Joseph M. Connors, Randy D. Gascoyne, German Ott, William R. Macon, Andreas Rosenwald - Blood 2018 被引用: 244

  15. Diffuse large B-cell lymphoma

    著者: Maurizio Martelli, Andrés J.M. Ferreri, Claudio Agostinelli, Alice Di Rocco, Michael Pfreundschuh, Stefano Pileri - Critical Reviews in Oncology/Hematology 2013 被引用: 447

  16. Clinical Impact of the Cell-of-Origin Classification and the MYC / BCL2 Dual Expresser Status in Diffuse Large B-Cell Lymphoma Treated Within Prospective Clinical Trials of the German High-Grade Non-Hodgkin's Lymphoma Study Group

    著者: Annette M. Staiger, Marita Ziepert, Heike Horn, David W. Scott, Thomas F.E. Barth, Heinz‐Wolfram Bernd, Alfred C. Feller, Wolfgang Hiddemann, Monika Szczepanowski, Michael Hummel, Harald Stein, Dido Lenze, Martin‐Leo Hansmann, Sylvia Hartmann, Peter Mӧller, Sergio Cogliatti, Georg Lenz, Lorenz Trümper, Markus Löffler, Norbert Schmitz, Michael Pfreundschuh, Andreas Rosenwald, German Ott, for the German High-Grade Lymphoma Study Group - Journal of Clinical Oncology 2017 被引用: 219

  17. Prognostic Value of Ki-67 Index, Cytology, and Growth Pattern in Mantle-Cell Lymphoma: Results From Randomized Trials of the European Mantle Cell Lymphoma Network

    著者: Eva Hoster, Andreas Rosenwald, Françoise Berger, Heinz‐Wolfram Bernd, Sylvia Hartmann, Christoph Loddenkemper, Thomas F.E. Barth, Nicole Brousse, Stefano Pileri, Grzegorz Rymkiewicz, Roman Kodet, Stephan Stilgenbauer, Roswitha Forstpointner, Catherine Thiéblemont, Michael Hallek, Bertrand Coiffier, Ursula Vehling‐Kaiser, Réda Bouabdallah, Lothar Kanz, Michael Pfreundschuh, Christian Schmidt, Vincent Ribrag, Wolfgang Hiddemann, Michael Unterhalt, Johanna C. Kluin-Nelemans, Olivier Hermine, Martin Dreyling, Wolfgang Hiddemann - Journal of Clinical Oncology 2016 被引用: 362

  18. Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial

    著者: Hartmut Goldschmidt, H M Lokhorst, E K, Bronno van der Holt, Igor Wolfgang Blau, Sonja Zweegman, Katja Weisel, Edo Vellenga, Michael Pfreundschuh, Marie José Kersten, Christof Scheid, Sandra Croockewit, Reinier Raymakers, Dirk Hose, Anna Potamianou, A. Jauch, Jens Hillengaß, Marian Stevens‐Kroef, Marc‐Steffen Raab, Annemiek Broijl, H. Lindemann, Gerard M.J. Bos, Peter Brossart, Marinus van Marwijk Kooy, Paula F. Ypma, Ulrich Duehrsen, Ron Schaafsma, Uta Bertsch, Thomas Hielscher, L. e. Jarari, Hans Salwender, Pieter Sonneveld - Leukemia 2017 被引用: 201

  19. Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

    著者: Judith Trotman, Sally F. Barrington, David Belada, Michel Meignan, Robert MacEwan, Carolyn Owen, Václav Ptáčník, András Rosta, Günter Fingerle‐Rowson, Jiawen Zhu, Tina Nielsen, Deniz Şahin, Wolfgang Hiddemann, Robert Marcus, Andrew Davies, Mark Hertzberg, Andrew Grigg, Paul Cannell, Hang Quach, Stephen Opat, Constantine S. Tam, Paula Marlton, Ann Janssens, Fritz Offner, Koen Van Eygen, Randeep Sangha, Pam McKay, Jonathan Wilson, Richard van der Jagt, Daryl Roitman, Marek Trněný, Jiřı́ Mayer, Katell Le Dû, Philippe Solal‐Céligny, Guillaume Cartron, Charles Foussard, Norbert Frickhofen, Peter Schmidt, Ullrich Graeven, Tobias Gaska, Rudolf Schlag, Martin Sökler, Gabriele Prange‐Krex, Axel Florschütz, Hans‐Walter Lindemann, Christoph Schimmelpfennig, Solveig Tonndorf, Mathias Hänel, Georg Heß, Enrico Schalk, Heiko Hütten, Gottfried Doelken, Michael Pfreundschuh, Ulrich Keller, Michael Herold, Roswitha Forstpointner, Ursula Vehling‐Kaiser, Martin Hoffmann, Zita Borbényi, M. Udvardy, Judit Demeter, Alessandro Rambaldi, Enrica Morra, Federico Massimo, Ignazio Majolino, Monica Balzarotti, Gianpietro Semenzato, Miguel Angel Canales Albendea, Francisco Javier Peñalver Párraga, Alfonso Soler Campos, Juan Manuel Sancho Cia, José Antonio Márquez Navarro, Carlos Grande García, Herman Nilsson‐Ehle, Helen O. McCarthy, Chris Pocock, Shalal Sadullah, Ram Malladi, John Radford, Ed Kanfer, Anton Kruger, Dominic Culligan, Martin J.S. Dyer, Ruth Pettengell, John Seymour, John G. Gribben, Saad Al‐Ismail, F. N. Al‐Refaie, Norbert Blesing, Christopher Macnamara, Ann O’Callaghan, Andrew Haynes, George Follows, Roderick J. Johnson, David Cunningham, Kristian M. Bowles, Graham P. Collins, Eve Gallop‐Evans, Stephen Robinson, Chezhian Subash ほか 108 名 - The Lancet Oncology 2018 被引用: 159

  20. Bortezomib Induction and Maintenance Treatment in Patients With Newly Diagnosed Multiple Myeloma: Results of the Randomized Phase III HOVON-65/ GMMG-HD4 Trial

    著者: Pieter Sonneveld, Ingo Schmidt‐Wolf, Bronno van der Holt, Laila el Jarari, Uta Bertsch, Hans Salwender, Sonja Zweegman, Edo Vellenga, Annemiek Broyl, Igor Wolfgang Blau, Katja Weisel, Shulamiet Wittebol, Gerard M.J. Bos, Marian Stevens‐Kroef, Christof Scheid, Michael Pfreundschuh, Dirk Hose, Anna Jauch, Helgi van de Velde, Reinier Raymakers, M Schaafsma, Marie José Kersten, Marinus van Marwijk-Kooy, Ulrich Duehrsen, Walter Lindemann, Pierre W. Wijermans, Henk M. Lokhorst, Hartmut Goldschmidt - Journal of Clinical Oncology 2012 被引用: 826

  21. Standard International Prognostic Index Remains a Valid Predictor of Outcome for Patients With Aggressive CD20+B-Cell Lymphoma in the Rituximab Era

    著者: Marita Ziepert, Dirk Hasenclever, Evelyn Kuhnt, Bertram Glaß, Norbert Schmitz, Michael Pfreundschuh, Markus Loeffler - Journal of Clinical Oncology 2010 被引用: 585

  22. Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p

    著者: Kai Neben, Henk M. Lokhorst, Anna Jauch, Uta Bertsch, Thomas Hielscher, Bronno van der Holt, Hans Salwender, Igor Wolfgang Blau, Katja Weisel, Michael Pfreundschuh, Christof Scheid, Ulrich Dührsen, Walter Lindemann, Ingo Schmidt‐Wolf, Norma Peter, Christian Teschendorf, Hans Martin, Mathias Haenel, Hans Guenter Derigs, Marc S. Raab, Anthony D. Ho, Helgi van de Velde, Dirk Hose, Pieter Sonneveld, Hartmut Goldschmidt - Blood 2011 被引用: 357

  23. Reduced-intensity chemotherapy and PET-guided radiotherapy in patients with advanced stage Hodgkin's lymphoma (HD15 trial): a randomised, open-label, phase 3 non-inferiority trial

    著者: Andreas Engert, Heinz Haverkamp, Carsten Kobe, Jana Marková, Christoph Renner, Antony D. Ho, Josée M. Zijlstra, Zdeněk Král, Michael Fuchs, Michael Hallek, Lothar Kanz, Hartmut Döhner, Bernd Dörken, Nicole Engel, Max S. Topp, Susanne Klutmann, Holger Amthauer, Andreas Bockisch, Regine Kluge, Clemens Kratochwil, Otmar Schober, Richard Greil, Reinhard Andreesen, Michael Kneba, Michael Pfreundschuh, Harald Stein, Hans Theodor Eich, Rolf‐Peter Müller, Markus Dietlein, Peter Borchmann, Volker Diehl - The Lancet 2012 被引用: 632

  24. Safety and efficacy of imatinib in CML over a period of 10 years: data from the randomized CML-study IV

    著者: Lida Kalmanti, Susanne Saußele, Michael Lauseker, M. C. Muller, Christian Dietz, Linda Heinrich, Benjamin Hanfstein, Ulrike Proetel, Alice Fabarius, Stefan W. Krause, Sébastien Rinaldetti, Jolanta Dengler, Christiane Falge, Elisabeth Oppliger Leibundgut, Andreas Burchert, Andreas Neubauer, Lothar Kanz, Frank Stegelmann, Michael Pfreundschuh, Karsten Spiekermann, Christof Scheid, Markus Pfirrmann, Andreas Hochhaus, Joerg Hasford, R. Hehlmann, for the SAKK and the German CML Study-Group - Leukemia 2015 被引用: 274